Molecular Profiling of 50,734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
Simion ChioseaSteven P HodakLinwah YipDevaprabu AbrahamChelsey K BaldwinZubair BalochSeza A GulecZeina C HannoushBryan R HaugenLija JosephAtil Y KargiElham KhanafsharMasha J LivhitsBryan McIverKepal PatelSnehal G PatelGregory W RandolphAshok R ShahaJyotirmay SharmaNikolaos StathatosAnnemieke van ZanteSally E CartyYuri E NikiforovMarina N NikiforovaPublished in: The Journal of clinical endocrinology and metabolism (2023)
In this series, 68% of BCIII-IV nodules were classified as negative by ThyroSeq, potentially preventing diagnostic surgery in this subset of patients. Specific genetic alterations were detected in most BCV-VI nodules, with a higher prevalence of BRAF and TERT mutationsand targetable gene fusions compared to BCIII-IV nodules, offering prognostic and therapeutic information for patient management.